Defining apoptosis-regulatory cascades of the epithelium is important for understanding carcinogenesis, since cancer cells are considered to arise as a result of the collapse of the cascades. We previously reported that a novel gene GASDERMIN (GSDM) is expressed in the stomach but suppressed in gastric cancer cell lines. Furthermore, in this study, we demonstrated that GSDM is expressed in the mucus-secreting pit cells of the gastric epithelium and frequently silenced in primary gastric cancers. We found that GSDM has a highly apoptotic activity and its expression is regulated by a transcription factor LIM domain only 1 (LMO1) through a sequence to which Runt-related transcription factor 3 (RUNX3) binds, in a GSDM promoter region. We observed coexpression of GSDM with LMO1, RUNX3 and type II transforming growth factor-b receptor (TGF-bRII) in the pit cells, and found that TGF-b upregulates the LMO1-and GSDMexpression in the gastric epithelial cell line and induces apoptosis, which was confirmed by the finding that the apoptosis induction is inhibited by suppression of each LMO1-, RUNX3-and GSDM expression, respectively. The present data suggest that TGF-b, LMO1, possibly RUNX3, and GSDM form a regulatory pathway for directing the pit cells to apoptosis.
Defining apoptosis-regulatory cascades of the epithelium is important for understanding carcinogenesis, since cancer cells are considered to arise as a result of the collapse of the cascades. We previously reported that a novel gene GASDERMIN (GSDM) is expressed in the stomach but suppressed in gastric cancer cell lines. Furthermore, in this study, we demonstrated that GSDM is expressed in the mucus-secreting pit cells of the gastric epithelium and frequently silenced in primary gastric cancers. We found that GSDM has a highly apoptotic activity and its expression is regulated by a transcription factor LIM domain only 1 (LMO1) through a sequence to which Runt-related transcription factor 3 (RUNX3) binds, in a GSDM promoter region. We observed coexpression of GSDM with LMO1, RUNX3 and type II transforming growth factor-b receptor (TGF-bRII) in the pit cells, and found that TGF-b upregulates the LMO1-and GSDMexpression in the gastric epithelial cell line and induces apoptosis, which was confirmed by the finding that the apoptosis induction is inhibited by suppression of each LMO1-, RUNX3-and GSDM expression, respectively.
Introduction
The gastric epithelium consists of tubular units of epithelial cells (Karam and Leblond, 1995) . Each unit is divided into four successive regions from surface to base: pit, isthmus, neck and gland. The isthmus or neck contains stem cells from which mature epithelial cells are derived and moved to the other two regions. Mucussecreting pit cells migrate up from progenitor cells toward the gastric lumen. The neck cells migrate down toward the base of the gland, where they give rise to pepsinogen-producing chief cells. The differentiated cells are eventually removed from the epithelium by apoptosis. Despite the fact that gastric cancer is one of the common causes of cancer-related deaths in the world, study on the regulatory mechanism for differentiation of gastric epithelial cells has not shown much progress.
GASDERMIN (GSDM) is a human homolog of mouse gene Gasdermin (Gsdm), which was isolated by positional cloning as a candidate of the gene responsible for two mouse mutants with epidermal hyperplasia: recombination-induced mutation 3 (Rim3) and Rex denuded (Re den ) (Sato et al., 1998; Saeki et al., 2000) . Gasdermin 3 (Gsdm3), one of the mouse homolog of GSDM/Gsdm, was reported as the responsible gene for Rim3 and other mutant mice with skin phenotype, and is considered to have some role in the epidermal differentiation (Runkel et al., 2004; Lunny et al., 2005) . Human GSDM is preferentially expressed in the gastric epithelium, but frequently silenced in gastric cancer cell lines (Saeki et al., 2000) . These findings in humans and mice suggest the possibility that GSDM/Gsdm contribute to the regulation of normal epithelial cell proliferation and/or differentiation.
Transforming growth factor-b (TGF-b) is known as a multifunctional growth factor in many developmental and physiological processes and is involved in the apoptosis of the gastric epithelium (Crawford et al., 1998) . Recently, study on Runt-related transcription factor 3 (Runx3) knockout (KO) mouse demonstrated that Runx3 is expressed in the surface portion of the pit region of mouse stomach and plays a crucial role in apoptosis of the gastric epithelium by TGF-b signalling and that the loss of RUNX3 expression is causally related to the genesis and progression of human gastric cancer (Li et al., 2002) . However, as there is a study reporting no expression of Runx3 in mouse gastric epithelium (Levanon et al., 2001) , its expression and role in human and mouse stomach are still controversial.
In this study, we show that GSDM has an apoptotic activity and an expression in the pit cells of human gastric epithelium, which is regulated by LIM domain only 1 (LMO1), and possibly RUNX3, in TGF-b signalling. The results suggest that those molecules form a regulatory pathway for directing the pit cells to apoptosis.
Results
GSDM, the human ortholog of mouse Gsdm, is expressed in gastric pit cells We isolated cDNA for GSDM, a human counterpart of mouse Gsdm (AB033595), by reverse transcription-PCR (RT-PCR) from the human gastric epithelium cDNA library. The human cDNA clone obtained has 89% similarity in amino-acid sequence to mouse Gsdm (data not shown). A database search revealed that the human cDNA sequence is located on the human chromosome 17q21, which is syntenic to the region containing Gsdm on mouse chromosome 11 and genomic Southern blot analysis demonstrated that only one Gsdm homolog is present in the human genome (Saeki et al., 2000) . Thus, we concluded that this cDNA clone encodes human GSDM. Mouse Gsdm expression has been identified in the esophagus, stomach and skin (Saeki et al., 2000) . Human GSDM mRNA, in a similar manner, was detected in the epithelium of the stomach, esophagus, mammary gland and skin (Figure 1 and data not shown).
To show the expression site of GSDM in human gastric epithelium, we carried out immunohistochemical studies. Our previous transfection study has shown cytoplasmic localization of mouse Gsdm in 293 cells which are not mucus-secreting cells (Saeki Figure 1 GSDM is expressed in the pit region of human gastric epithelium. (a) GSDM expression (brownish staining) is demonstrated in the pit cells of gastric epithelium by immunohistochemistry. Gastric epithelium consists of four regions. The isthmus and neck regions contain stem cells and the pit region contains differentiated pit cells. Higher magnification is shown in the center and right panels. The GSDM protein is observed in a perinuclear region of the cytoplasm as the mature pit cells contain a significant amount of mucous in their cytoplasm. Scale bar, 100 mm. (b) RT-PCR analysis combined with LCM shows GSDM expression in the gastric pit region where a pit cell marker MUC5AC, is expressed but a proliferating cell marker, PCNA, is not. Expression of LMO1, RUNX3, TGF-bRII is also demonstrated exclusively in the pit region. The result suggests that GSDM and other molecules are expressed in differentiated cells in the pit region. RUNX1 transcript, but not RUNX2 is also detected in the pit region. (c) Immunohistochemistry shows colocalizaion in pit cells of the molecules; GSDM (blue)/LMO1 (red), GSDM (blue)/RUNX3 (red) and GSDM (blue)/TGFbRII (red), respectively. RUNX3 and TGF-bRII are observed diffusely in the pit cell region with partial overlapping of GSDM; on the contrary, LMO1 shows scattered distribution colocalized with the cells in which GSDM is highly expressed. Merged figures demonstrate colocalization of the molecules.
TGF-b/LMO1/GSDM pathway in gastric pit cells N Saeki et al et al., 2000) . The mature pit cells are known to containa significant amount of mucus in their cytoplasm. Accordingly, the cytoplasmic proteins generally accumulate in a perinuclear region of the cytoplasm. Actually, GSDM protein was observed in the region (Figure 1a ). To confirm GSDM mRNA expression in the pit cells, we carried out RT-PCR analysis combined with a laser-captured microdissection (LCM) procedure as described in our previous study (Aoyagi et al., 2003) . With this procedure, the GSDM mRNA was detected predominantly in the pit region among the three regions of pit, isthmus/neck and gland (Figure 1b) . The expression of a pit cell marker, mucin 5, subtypes A and C (MUC5AC) (De Bolos et al., 1995; Ho et al., 1995) was significantly higher in the pit region, while a proliferating cell marker, proliferating cell nuclear antigen (PCNA), was detected preferentially in the isthmus/neck region ( Figure 1b) . Other specific or preferential expression of three markers (ATP4B, GIF and MUC6) has been confirmed in the gland region by our previous studies (Nishigaki et al., 2005; Fukaya et al., 2006) . The expression pattern suggests that GSDM is expressed in the differentiated cells rather than in proliferating cells.
GSDM is frequently silenced in primary gastric cancers as well as gastric cancer cell lines Our previous study demonstrated that GSDM is frequently silenced in gastric cancer cell lines (Saeki et al., 2000) . In this study, we examined whether GSDM is actually silenced in primary gastric cancers. The RT-PCR analysis on surgical specimens revealed that no or quite low GSDM mRNA was detected in the 3 of the 8 intestinal type gastric cancers (Figure 2a , left panel, lanes 3-5) or in 8 of the 10 diffuse type gastric cancers (Figure 2a , right panel, lanes 1-3, 5, 7-10). As a result, eleven out of the 18 primary gastric cancers (61%) expressed no or quite low GSDM mRNA.
As DNA methylaion is a major cause of gene silencing in cancer cells, we examined whether the silencing in gastric cancer is due to DNA methylation. RT-PCR analysis on 11 gastric cancer cell lines showed that GSDM was silenced in 8 cell lines, MKN28, MKN74, HSC39, HSC44, HSC58, HSC60, OCUM2M and KATOIII (Figure 2b ). In the other three cell lines, HSC43, HSC57 and HSC59, GSDM mRNA was detected by RT-PCR; however, those expression levels are so small that the transcripts were unable to be detected by northern blot analysis with a conventional The cell growth-inhibitory activity of GSDM was examined by colony formation assay of the gastric cancer cell lines MKN28, which completely lost the endogeneous expression of GSDM. Introduced into MKN28, GSDM reduces the colony count to 20% of that transfected with an empty vector, while the anti-sense sequence of GSDM has no effect. (e) Caspase 3/7 assay with transfection of GSDM-expression vectors reveals apoptosis-inducing activity of GSDM both in HSC59 and MKN28 cells. Caspase Inhibitor, zVAD. (f) TUNEL assay demonstrates apoptosis induction by GSDM in HSC59 and MKN28 within 24 h after the transfection. The cells with a brownish-stained nucleus are the result of apoptosis. Scale bar, 20 mm.
exposure of the blot to the film (Saeki et al., 2000) . By treatment with both AZA, an inhibitor of DNA methyltransferase, and TSA, an inhibitor of histone deacetylase, the expression of GSDM was restored in six (HSC39, HSC44, HSC58, HSC60, OCUM2M and KATOIII) out of the eight gastric cancer cell lines with no GSDM expression (Figure 2c ). These data suggested that silencing of GSDM in gastric cancer cells is mainly caused by methylation of GSDM gene and/or by methylation of genes involved in the regulation for GSDM expression.
GSDM has an apoptosis-inducing activity Both facts -high expression in differentiated gastric pit cells ( Figure 1 ) and the frequent silencing of GSDM in gastric cancers (Figure 2a -c) -suggest the possibility that GSDM has a negative effect on epithelial cell proliferation. Thus, we carried out colony formation assay to examine whether GSDM has cell growth inhibition activity. When the MKN28 cells were transfected with a GSDM-expression vector, the number of G418-resistant colonies was clearly reduced in comparison with the transfection of an antisense GSDM construct ( Figure 2d ). The caspase assay showed apoptosis induction in both MKN28 and HSC59 in which a GSDM-expression vector had been introduced ( Figure 2e ). The apoptosis inducing activity of GSDM was also demonstrated by TUNEL assay on the HSC59 and MKN28 cells ( Figure 2f ). These results suggested that the apoptosis induction by GSDM is one of the causes of decreased colony formation.
The GSDM promoter for gastric expression is identified in the upstream region in 400 bp distance from the transcription starting site To reveal the regulating molecules for gastric expression of GSDM, we tried to identify the region critical for gastric expression in the GSDM promoter. The procedure of 5 0 -RACE method disclosed that, in the stomach, the transcription is initiated from about 1.6 kb upstream of the translation initiation codon (data not shown). In a luciferase assay with HSC59, a reporter construct with the fragment covering 0.4 kb upstream to the transcription starting site exhibits the most significant enhancement of the reporter activity (À0.4 k, Figure 3a ) and truncation of this fragment reduces the reporter activity (data not shown). We therefore concluded that the critical regulatory region resides in the À0.4 kb fragment, and named it the À400 nt GSDM-regulatory region. A similar result was obtained with HSC57 cells that express GSDM but, to the contrary, in MKN28 cells that had lost GSDM expression, the same region had no effect on the reporter activity ( Figure 3a ). Both the cell lines, HSC57 and HSC59, have regulatory molecules that activate GSDM promoter. As GSDM expression is restricted to the differentiated pit cells in the normal gastric epithelium (Figure 1 ), these two cell lines could be useful for studies on transcriptional regulation of GSDM as cultured cells representing pit cells.
Next, using public computer retrieval (TFBIND http://tfbind.ims.u-tokyo.ac.jp), we searched the À400 nt GSDM-regulatory region for consensus sequences to which known transcription factors bind, and obtained several sequences similar to the binding consensuses of several known transcription factors, which included Runt-domain-binding consensus, in the À400 nt GSDM-regulatory region. The sequences were designated as the RUNX-binding sequence candidates (RBSC, Figure 3b ). We introduced a mutation into all the RBSC respectively and carried out a reporter assay in the same manner using HSC59. As a result, when a mutation (TGTGGTA to TGTAATA) was introduced into the RBSC9 located at the À106 to À100 nt position, which is perfectly matched with the Runt-domainbinding consensus, the reporter activity of the À400 nt GSDM-regulatory region construct significantly reduced to the level of basal activity of the reporter vector itself (RBSC9m, Figure 3b , right panel). Thus, now the Runtdomain-binding consensus at the À100 nt position became a most interesting sequence in the investigation of the regulatory region ( Figure 3c ). Although RBSC2 has less similarity to the Runt-domain-binding consensus than RBSC9, it could be involved in the regulation, as the mutation has effect on the reporter activity ( Figure 3b ).
The computer retrieval also detected the sequence TGCCAGGTGTGG in the À113 to À102 nt position within the À400 nt GSDM-regulatory region as LMO2-complex-binding consensus ( Figure 3c ). As a gene expression profiling using microarrays had revealed LMO1 expression both in HSC59 and in the gastric pit region (data not shown), we also listed LMO1 as the candidate of the protein binding to the sequence, in addition to RUNX3.
Both RUNX3 and LMO1 are expressed in the pit region and bind to the GSDM promoter in vitro To examine whether LMO1 and any member of RUNX family are expressed in the pit cells, we carried out RT-PCR analysis combined with the LCM procedure on the human gastric mucosa. The LMO1 transcript is detected in the pit region, and in the RUNX family, both RUNX1 and RUNX3 transcripts were detected in the pit region (Figure 1b) . In addition, immunohistochemistry also revealed that LMO1 and RUNX3 are localized in the cells of the pit region (Figure 1c ). In mice, in situ hybridization of Runx3 demonstrated the expression in both mucous cells in the pit region and parietal cells in the gland region (Li et al., 2002) ; however, an immunohistochemical study showed that Runx1, but not Runx3, was expressed in the mouse gastric epithelium (Bae and Ito, 2003; Levanon et al., 2003) . Thus, although the Runx3 expression is still unclear in mice, our data showed that, in humans, RUNX1 and RUNX3 mRNAs were detected exclusively in the pit region but that no RUNX2 mRNA was detected (Figure 1b) .
To examine in vitro binding of the candidate transcription factors, we performed an electrophoretic TGF-b/LMO1/GSDM pathway in gastric pit cells N Saeki et al mobility shift assay (EMSA) using a 43-mer probe containing the RBSC9 (Figure 3c ). RT-PCR revealed that LMO1 and RUNX3 are expressed in HSC59 cells ( Figure 5a ). A nuclear extract of HSC59 produced shifted bands (arrow in Figure 4 ) when incubated with the probe. The shifted bands disappeared by pretreatment of the HSC59 nuclear extract with an anti-RUNX3 antibody and also by pretreatment with anti-LMO1 antibody (Figure 4 ). This anti-RUNX3 antibody, recognizing the epitope corresponding to amino-acid residues 38-54 in a Runt-domain of human RUNX3, was previously demonstrated to be unsuitable for the super-shift assay, as it reduced the shifted band rather than super-shifted it (Meyers et al., 1996) . The anti-RUNX1 and anti-LMO2 antibodies did not affect the shifted band (Figure 4 ) and no actual RUNX1-binding site was identified by EMSA using the whole sequence of the À400 nt GSDM-regulatory region as the probe (data not shown). These results indicated the binding of RUNX3 and LMO1 to RBSC9 in vitro. Thus we re-designated RBSC9 as the À100 nt LMO1/Rx3 consensus. Both simultaneous and respective treatments with the anti-LMO1 and anti-RUNX3 antibodies produced a shifted band with the same mobility (arrowhead in Figure 4) , which was smaller in size than the band (arrow in Figure 4 ) produced without the Figure 3 The À400 nt GSDM-regulatory region is critical for gastric expression of GSDM. (a) Luciferase reporter assay using human gastric cancer cell lines. The activity of each reporter construct is shown as the ratio to that of basic vectors. In HSC59, which expresses GSDM, the À0.4 kb upstream sequence from a transcription starting site shows significant promoter activity. The promoter activity is also demonstrated in another cell line expressing GSDM, HSC57. In MKN28 expressing no GSDM, the sequence shows no promoter activity. Thus, we designated the sequence as the À400 nt GSDM-regulatory region as it contains the regulatory region for gastric expression of GSDM. Bars, s.d. (b) RUNX-binding sequence candidates (RBSCs) in the À400 nt GSDM-regulatory region and their mutation effect on the reporter activity. The region contains 10 RBSCs. Two-base substitution (asterisked bases to AA or TT) was introduced into each RBSC included in the reporter construct, respectively. The mutation (TGTGGTA to TGTAATA) in RBSC9 (RBSC9m) shows the most reductive effect on the reporter activity, suppressing it to 30% of the wild-type, which is almost equal to the basal activity of the vector (shown as Vector). Bars, s.d. (c) RBSC9 located at the À100 nt position in the À400 nt GSDM-regulatory region was designated as the À100 nt LMO1/Rx3 consensus as binding of LMO1 and RUNX3 was demonstrated by EMSA (Figure 4) . The base at position þ 1 is the transcription starting site. Underline, Runt-binding consensus. Bar, a probe sequence used in EMSA. Asterisks, base substituted in the mutated competitor used in EMSA.
TGF-b/LMO1/GSDM pathway in gastric pit cells N Saeki et al antibody treatment. This implies that both the anti-RUNX3 and anti-LMO1 antibodies independently inhibit the binding of both RUNX3 and LMO1 to the probe. The result suggests that RUNX3 and LMO1 may cooperatively bind to the À100 nt LMO1/Rx3 consensus. The smaller shifted band (arrowhead) without any reduction in the intensity implies the binding of another transcription factor to the probe, which may also be required for GSDM expression. Other three antibodies to the transcription factors related to RUNX3 and to LMO1, anti-RUNX1, anti-LMO2 and anti-LMO4 antibodies, did not affect the mobility of the shifted band (Figure 4 ).
TGF-b upregulates GSDM expression through LMO1 induction
Because it is reported that RUNX3 is involved in TGF-b signalling for apoptosis in the gastric epithelium (Li et al., 2002) , we investigated whether GSDM is involved in the TGF-b/RUNX3 pathway. In this context, first of all, we observed expression of Type II TGF-b receptor (TGF-bRII) in the pit cells, colocalized with GSDM by immunohistochemistry (Figure 1c) . RT-PCR analysis on the microdissected specimens also demonstrated TGF-bRII transcripts in the pit region (Figure 1b) . LMO1 was expressed diffusely among the pit cells but localized in the cells that expressed GSDM strongly, which implies that LMO1 was observed only in the cells entering into the apoptotic process and that GSDM was further upregulated by the LMO1 in them. RT-PCR analysis revealed that TGF-b apparently enhances LMO1 expression and also GSDM expression in HSC59 cells but not in MKN28, and that TGF-b does not upregulate RUNX3 expression in HSC59 or MKN28 (Figure 5a ). This result seems implicative because, as demonstrated later, HSC59 cells, but not MKN28 cells, are sensitive to the apoptosis induction activity of TGF-b (Yanagihara and Tsumuraya, 1992) . These facts indicate the relation between the apoptosis induction by TGF-b and the LMO1 expression. Although the increment of GSDM mRNA by TGF-b is relatively small when compared with the increment of LMO1 mRNA in HSC59 cells, the dose effect of TGF-b on the GSDM mRNA induction was confirmed by quantitative RT-PCR (Figure 5b ). GSDM protein induction at 24 h after TGF-b treatment was also confirmed by western blot analysis using anti-GSDM antibody (Figure 5c ). Consistent with the induction, we found that TGF-b increases transcriptional activity of the À400 nt GSDM-regulatory region in HSC59 but not in MKN28 (Figure 5d ).
LMO1 binds to the À400 nt GSDM-regulatory region in HSC59 cells in vivo To demonstrate in vivo interaction between LMO1 and its binding site in the À400 nt GSDM-regulatory region, we performed the chromatin immunoprecipitation (ChIP) assay (Figure 5e ). Without TGF-b treatment of HSC59 cells, the sequence that rested near the binding site (shown as binding site primer in the Figure 5e ) was not detected by PCR in the DNA sample precipitated with an anti-LMO1 antibody, even in the condition of the appearance of the band of a nonspecific background in the DNA precipitated with a goat serum, which was prepared as a negative control (data not shown). With TGF-b treatment, the sequence near the binding site was detected in the DNA precipitated with the anti-LMO1 antibody, but not in the DNA precipitated with an anti-LMO2 antibody (Figure 5e ). In the DNA precipitated with the anti-LMO1 antibody, the sequence that rested at a 13 kb distance from the LMO1-binding site in the À400 nt GSDM-regulatory region was not observed (control primer). This result indicates that TGF-b promotes the recruitment of LMO1 to the binding site in the À400 nt GSDM-regulatory region, resulting in GSDM expression. In conclusion, the ChIP assay successfully demonstrates in vivo interaction between LMO1 and its binding site in the À400 nt GSDMregulatory region, especially in the condition with EMSA was performed with HSC59 nuclear extract using the sequence containing the À100 nt LMO1/Rx3 consensus as a probe. RUNX3 and LMO1 bind to the probe (arrow). For pre-masking, the HSC59 nuclear extract was incubated with anti-RUNX3, anti-RUNX1, anti-LMO1, anti-LMO2 and anti-LMO4 antibodies, respectively, before binding reaction to the probe. The anti-RUNX3 and anti-LMO1 antibodies reduce the intensity of the shifted band (arrow), but the anti-RUNX1, anti-LMO2 and anti-LMO4 do not. The intensity of the shifted bands is also reduced by adding non-labelled competitor (competitor). In the simultaneous use of both the anti-RUNX3 and anti-LMO1 antibodies for immunedepletion, a shifted band with different mobility is still observed (arrowhead), which implies that another molecule binds to the probe.
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TGF-b stimulation. This is strong proof for actual in vivo protein-DNA interaction, suggesting that TGF-b promotes the recruitment of LMO1 to its binding site in the À400 nt GSDM-regulatory region, which upregulates GSDM expression. We also carried out a ChIP assay using the anti-RUNX3 antibody (anti-AML2 antibody provided by Oncogene Research Product), however, it failed to demonstrate the recruitment of RUNX3 to the binding site (data not shown). We speculate this may be due to the quality of the antibody.
We have also tried to the immunoprecipitation to demonstrate the FLAG-Runx3 and myc-LMO1 interaction, but failed. It is probably due to small amount of the complex in the cells and also due to weak interaction, both of which is originated from requirement of the binding sequence on DNA in the LMO1-RUNX3 interaction. Instead of demonstrating the in vivo binding by the immunoprecipitation, we observed that LMO1-ECFP and Runx3-EYFP colocalize in HSC59 nucleus (Figure 5f ).
Although no strong proof was obtained for in vivo binding of RUNX3 to the GSDM promoter, the present data suggest that GSDM expression is upregulated by a transcriptional factor LMO1 whose expression is enhanced by TGF-b. RT-PCR analysis shows the increased mRNA expression of both GSDM and LMO1, but no upregulation of RUNX3 in HSC59 cultured in TGF-b-containing medium (2 ng/ml). In MKN28, no GSDM transcript is detected even after the TGF-b treatment. In MKN28, which is sensitive to the apoptosis-inducing effect of GSDM, but not to that of TGF-b, neither LMO1 nor RUNX3 is expressed or upregulated by TGF-b. (b) The dose effect of TGF-b on the GSDM mRNA induction was confirmed by quantitative PCR. The GSDM mRNA is increased in a dose-dependent manner (0, 2, 5 and 10 ng/ml). Black bars, the mean of the fold change on triplicated experiments (right panel). As a representative result, GSDM RT-PCR products at 0 and 24 h after TGF-b treatment with 10 ng/ml are shown (right small panel). (c) GSDM protein, which is not detected by western blot analysis in the cells before TGF-b treatment, is increased to be detectable after TGF-b stimulation (arrow). (d) TGF-b increases the reporter activity in HSC59 but not in MKN28. The cells were transfected with the reporter construct for the À400 nt GSDM-regulatory region. Relative luciferase activity of the cells incubated with TGF-b to that without TGF-b is shown for each cell line. Bars, s.d. (e) ChIP assay demonstrates that TGF-b promotes the recruitment of LMO1 to its binding site (the À100 nt LMO1/Rx3 consensus) in the À400 nt GSDM-regulatory region. The binding site primer is designed for detection of the sequence near the LMO1-binding site in the À400 nt GSDM-regulatory region, and the control primer is for the detection of sequence in the 13 kb of distance from the LMO1-binding site. (f) LMO1-ECFP (blue dots) and Runx3-EYFP (yellow dots) colocalize in the HSC59 nucleus (white dots in the merged figure) . DAPI stains nuclei.
The apoptosis induction by TGF-b is inhibited by suppressing GSDM, LMO1 and RUNX3, respectively In addition to GSDM (Figure 2e and f), we also observed the apoptosis induction in HSC59 by TGF-b and LMO1, respectively (Figure 6a ). Then, we examined the effect of suppression of LMO1, RUNX3 and GSDM, respectively, on the apoptosis induction in HSC59 by TGF-b. The RT-PCR demonstrated that the short interfering RNAs (siRNAs) for silencing LMO1, RUNX3 and GSDM, respectively, have a suppression effect on the cells, but those are partial. The transcripts were retained in both the cells with and without TGF-b treatment (Figure 6b ). Reporter assay on the À400 nt GSDM-regulatory region also showed that the siRNAs for LMO1 and RUNX3, respectively, suppresses the increment effect of TGF-b (data not shown). By the caspase assay, it was demonstrated that the siRNA for GSDM suppression results in a 60% reduction (83-50%, Figure 6c ) of the apoptosis of the TGF-b-treated HSC59. The siRNAs for RUNX3 and LMO1 show about a 32% reduction (81-55%) and a 50% reduction (76-39%), respectively.
Discussion
In this study, we demonstrated that TGF-b upregulates GSDM via induction of LMO1 in HSC59 cells that seem to share some properties of gastric pit cells, and that LMO1 and GSDM are colocalized in the pit region. All the results in this study support the idea that GSDM may have a function in the regulation of the apoptosis of gastric epithelial cells and is a strong target of LMO1 in TGF-b signalling for apoptosis induction of the pit cells. LMO1 is a member of LMO protein family, which consists of four members, LMO1, LMO2, LMO3 and LMO4. They are a transcriptional regulator and have distinct expression patterns in embryonic and adult tissues, suggesting crucial roles in cell fate determination (Foroni et al., 1992; Kenny et al., 1998) . As LMO1 is a nuclear protein with no DNA-binding activity, it is considered that it interacts with other molecules through its LIM domains when it acts in transcriptional regulation. Though LMO1 was originally isolated as a candidate oncogene for T-cell acute lymphoblastic leukemia (McGuire et al., 1989; Rabbitts, 1998) , our study disclosed a crucial role of LMO1 in gastric epithelium differentiation and it may be also involved in gastric carcinogenesis. Recently, phenotypic discrepancies between two Runx3-KO mice gave rise to some argument about the function of Runx3 in the gastric epithelium (Levanon et al., 2002 (Levanon et al., , 2003 Li et al., 2002; Bae and Ito, 2003) . Moreover, it was reported that Runx3 is not expressed in the gastric epithelium (Levanon et al., 2001) , which negates the involvement of Runx3 in gastric carcinogenesis. The present study demonstrated that RUNX3 is indeed expressed in the gastric epithelium and that it is likely to be involved in apoptosis induction in the gastric epithelium. Thus, RUNX3 could be involved in gastric carcinogenesis by regulating GSDM.
In addition to the result of this study, some findings in Runx3-KO mouse (Li et al., 2002) also support the involvement of RUNX3 in GSDM regulation. We identified GSDM expression, but not RUNX3, in esophageal epithelium and a second promoter for esophagusspecific expression, and observed that GSDM induces apoptosis of esophageal cell lines (data not shown). In the homozygous Runx3-KO mouse, while only few apoptotic cells were found in the gastric epithelium, it was intact in the esophageal epithelium. These findings suggest that, in the esophageal epithelium, TGF-b induces apoptosis by upregulating GSDM through the esophagus-specific promoter, which is regulated by other transcription factor than RUNX3. GSDM is a unique protein with no known significant motif. The mechanism of apoptosis induction by GSDM is actually unknown so far. However, using an affinity chromatography, we have obtained several molecules that bind to GSDM, one of which was reported to be involved in the apoptotic process (data not shown). As the molecule was co-precipitated with GSDM by an immunoprecipitation procedure, it is speculated that the molecule actually interacts with GSDM in vivo. We suppose that, weakly expressed in differentiated pit cells, GSDM has some roles in the cells, which may be related to maintenance of the differentiated state, and that this weak expression may be regulated by a cascade other than TGF-b signalling. In the process of withdrawal from the epithelium, GSDM is additionally induced by TGF-b signalling and modulates the function and/or location of the molecule involved in apoptosis, which is the trigger of initiation of the apoptotic process.
In conclusion, we demonstrated that the three molecules, LMO1, RUNX3 and GSDM, are expressed in the gastric pit cells and that LMO1, possibly with RUNX3, actually regulates GSDM expression, which finally induces apoptosis of the cells of gastric epithelium origin. All the findings in this study support that GSDM is involved in one of the regulation pathways for apoptosis induction in the pit cells of human gastric epithelium. The molecules involved in this regulation have potential utility for gastric cancer therapy.
Materials and methods

Tissue samples and cell lines
Human surgical specimens were obtained from 10 diffuse type gastric cancers and 8 intestinal type gastric cancers. We used three cell lines derived from intestinal type gastric cancer, HSC57, MKN28 and MKN74 (Sekiguchi and Suzuki, 1994; Yanagihara et al., 2004) , and eight cell lines derived from the diffuse type of gastric cancer cell lines, HSC39, HSC43, HSC44, HCS58, HSC59, HSC60, OCUM2M and KATO III (Sekiguchi et al., 1978; Fujihara et al., 1998; Yanagihara et al., 2004) . All the cell lines were maintained in Dulbecco's modified Eagle medium (Invitrogene, Carlsbad, CA, USA).
cDNA isolation
Human GSDM cDNA was isolated from the cDNA library of the human stomach by RT-PCR with a primer set: 5 0 -GGAATTCCCAGAGACATGACC-3 0 and 5 0 -GACTAGT CATGAAGCAGACG-3 0 . The nucleotide sequence of human GASDERMIN has been submitted to the DNA Data Bank of Japan (DDBJ, http://www.ddbj.nig.ac.jp) with the accession number AB093591. Human LMO1 cDNA was isolated from the cDNA library of HSC59 by RT-PCR with a primer set: 5 0 -GCCATGGTGGTGCTGGACAAGG-3 0 and 5 0 -CCAGCCT GCACTGGTAGAGTGG-3 0 .
Anti-GSDM antibody
The carboxy-terminal side of the GSDM protein (302-445 aa residues) was purified as a His-tagged protein using QIAexpress System (QIAGEN, Tokyo, Japan). Anti-GSDM serum was prepared by immunizing rabbits with the protein and purified using protein A sepharose by Sawady Technology, Tokyo, Japan. The specificity was tested by western blot analysis on purified GSDM-FLAG fusion protein.
Iimmunohistochemistry
Sections of the gastric mucosa were incubated with the anti-GSDM antibody in phosphate-buffered saline also containing 3% goat serum. After incubation with the secondary antibody, a streptavidin-peroxidase solution was applied to the sections followed by a development solution containing diaminobenzidine. For double staining, sections were treated with trypsin solution for antigen unmasking and incubated with mixtures of primary antibodies; anti-GSDM and anti-LMO1 (Santa Cruz Biochemistry, Santa Cruz, CA, USA), anti-GSDM and anti-AML2 (Calbiochem, Darmstadt, Germany), and anti-GSDM and anti-TGF-bRII (Santa Cruz Biochemistry), respectively. After incubation with a mixture of appropriate secondary antibodies conjugated with FITC or TRITC (Santa Cruz Biochemistry), the sections were observed by using Zeiss LSM510 META Confocal Imaging System (Carl Zeiss, Tokyo, Japan).
Laser-captured microdissection and RT-PCR Surgical specimens of the normal human stomach were embedded in TissueTek OCT medium (VWR Scientific Product, West Chester, PA, USA) and snap-frozen in liquid nitrogen. The cryostat sections (8 mm) were microdissected with a PixCell II LCM system (Arcturus Engineering, Mountain View, CA, USA). The mRNA was isolated and amplified by our previously developed method (Aoyagi et al., 2003) . RT-PCR was carried out using primer sets designed for detecting the 3 0 side of cDNA of each gene: for GSDM, 5 0 -GATGGAACAGAACTTCCTGC-3 0 and 5 0 -CTGAAATGC CCTTAGGTGGT-3 0 , for LMO1, 5 0 -TGGCACCTTTGAAT CCCAAG-3 0 and 5 0 -AGAACTTCTCCGTCCTCGAT-3 0 , for RUNX3, 5 0 -CACGAGGAAAGGAAGACGTT-3 0 and 5 0 -CT GTACAAGCAAGTTGTGCG-3 0 , for RUNX2, 5 0 -CTTCGT CAGGATCCTATCAG-3 0 and 5 0 -TCATCCATTCTGCCAC TAGA-3 0 , for RUNX1, 5 0 -TCATGTCACTACTGTCCGTG 3 0 and 5 0 -CACTGTTCTGAAGTCCTGCT-3 0 . The PCR were performed under conditions with 30-35 cycles of three steps of temperature, 951C for 1 min 551C for 1 min, and 721C for 1 min, using ExTaq polymerase (TAKARA BIO, Shiga, Japan). Other RT-PCR primers used have been described in our previous study (Fukaya et al., 2006) . For reactivation of GSDM, gastric cancer cell lines were treated with 1 mM 5-aza-2 0 -deoxycytidine (AZA, Sigma, Saint Louis, MO, USA) for 48 h, followed by addition of 1 mM Tricostatin A (TSA, Sigma) for a further 12 and 24 h.
Quantitative RT-PCR Total RNA was isolated from HSC59 cells that were incubated for 24 h in the medium containing TGF-b1 (Sigma, 0, 2, 5, 10 ng/ml), converted to the first strands, and then applied to real-time PCR with iQ Syber Green Supermix (BioRad, Hercules, CA, USA) under conditions with 40 cycles of three steps of temperature: 951C for 30 s, 601C for 30 s and 721C for 30 s, using 7300 Sequence Detector (Applied Biosystems, Foster, CA, USA).
Colony formation assay GSDM cDNA and its antisense sequence were introduced to the pcDNA3.1 expression vector (Invitrogene), respectively. MKN28 cells were transfected with 10 mg of each construct per 15-cm dish containing 1 Â 10 7 cells using Lipofectamine (Invitrogen) and the reaction was terminated in 2 h. After 24 h incubation, 1 Â 10 5 transfected cells were seeded onto a TGF-b/LMO1/GSDM pathway in gastric pit cells N Saeki et al 100-mm dish and maintained in the medium supplemented with 600 mg/ml of G418 (Invitrogen). Colonies stained with May-Giemsa were counted at 12-14 days after G418 addition.
TUNEL assay Apoptotic cells were detected by an ApopTag peroxidase in situ apoptosis assay kit (Intergen, Burlington, MA, USA).
To check GSDM for the ability of apoptosis induction, pcDNA3.1 expression vector was used for overexpression of GSDM and LMO1 in HSC59 and MKN28 cells. These were transfected using SuperFect Transfection Reagent (QIAGEN). For apoptosis induction, TGF-b1 (Sigma) was added to the medium at a concentration of 2 ng/ml.
Reporter assay DNA fragments with various lengths of the upstream region of the GSDM gene were obtained by long PCR using human DNA as a template. The primer set, 5 0 -GCTAGCTGGGAGC TTACTCTGTTCAGAAAGGAG-3 0 and 5 0 -CTCGAGGCT TACAATACCCGCTTCCGGATCTGAAG-3 0 , was used to isolate the 6 kb upstream fragment. The 0.4 kb upstream fragment was produced by digesting the 6 kb fragment by BalI. The genomic DNA fragments were inserted into a pGL3 basic vector (Promega, Madison, WI, USA). One microgram of the reporter constructs, was introduced into 2.5 Â 10 3 cells with the Renilla luciferase control reporter vector (pRL-SV40 vector, Promega) using SuperFect Transfection Reagent (QIAGEN). The luciferase assay was performed 24 h after the reporter introduction, using a Dual-Luciferase Reporter Assay System (Promega). The experiment was repeated in triplicate. The constructs with mutation in RBSCs were prepared by Hitachi High-Technologies Corporation Ltd, Tokyo, Japan.
Electrophoretic mobility shift assay Binding reaction was performed by incubating the nuclear extract of HSC59 with a 32 P-labelled double-stranded DNA probe, 5 0 -GTGCCAGGTGTGGTACTTGCTGCTGCAGAG GTGACTAAGACCC-3 0 , in a buffer containing 10 mM TrisHCl, (pH 7.5), 5% Glycerol, 1 mM dithiothreitol, 2 mM ethylenediamine tetra acetic acid (EDTA) and 100 ng/ml poly(dIdC). Immunedepletion assay was carried out by incubating 6 mg of the nuclear extract with 2 mg of anti-RUNX3 antibody (Oncogene Research Products, Cambridge, MA, USA), anti-RUNX1 (Santa Cruz), anti-LMO1 (Santa Cruz), anti-LMO2 (Santa Cruz) and anti-LMO4 (Santa Cruz), respectively, before the binding reaction. After the binding reaction with the nuclear extract, the probe was loaded on a 6% polyacrylamide gel. The probe with substitution, 5 0 -GTGCCA GGTGTAATACTTGCTGCTGCAGAGGTGACTAAGAC CC-3 0 , was prepared as the mutated competitor. The mouse Runx3 partial cDNA was used as the unrelated competitor.
Western blot analysis HSC59 cells were treated with TGF-b1 (Sigma) of 2 ng/ml in the medium and the cell lysate was prepared using CelLytic-M cell lysis reagent (Sigma). Twenty microgram of protein per lane was loaded on 7.5% SDS-polyacrylamide gel and then immunoblotted with the anti-GSDM antibody (5 mg/ml) and anti-HISTONE H1 antibody (Santa Cruz, 1 mg/ml), respectively. The signals were detected using ECL Plus Western Blotting Detection Reagent (GE Healthcare Bio-Science, Tokyo, Japan).
Chromatin immunoprecipitation assay
The HSC59 cells, 10 7 in 100-mm dish, were treated with TGFb1 (2 ng/ml, Sigma) for 24 h and then fixed with formaldehyde (0.5% in the medium). The cells were suspended in an SDSlysis buffer, sonicated and then diluted 100-fold in a Triton X-lysis buffer. Two ml of the cell lysate was pre-blocked with Salmon sperm DNA/Protein A agarose (Upstate, Charlottesville, VA, USA). After centrifuging, 100 ml of the supernatant was reserved for the control sample, and precipitated with ethanol, and finally resuspended in 50 ml of water. Ten micrograms of anti-LMO1 antibody (Santa Cruz) antibody, the anti-LMO2 antibody (Santa Cruz) and goat serum (Santa Cruz), respectively, were added to 300 ml of the supernatant, and incubated at 41C with rotation. Salmon sperm DNA/ Protein A agarose was incubated with each the cell lysate for 6 h at 41C and washed with the series of buffer; buffer 1 (0.1% SDS, 1% Triton X 100, 2 mM EDTA 20 mM Tris-HCl (pH 8.1), 150 mM NaCl), buffer 2 (0.1% SDS, 1% Triton X 100, 2 mM EDTA 20 mM Tris-HCl (pH 8.1), 500 mM NaCl), buffer 3 (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, (pH 8.1)), TE (10 mM Tris-HCl, (pH 7.5), 1 mM EDTA). The protein-DNA complex was eluted and DNA was purified and resuspended in 15 ml water. PCR was performed with 35 cycles of 3 steps: 941C for 1 min, 551C for 1 min and 721C for 1 min, with 2 ml of the DNA solution as templates, using ExTaq polymerase. The primers, 5 0 -CCAG GAGGTGACCTGAATT-3 0 and 5 0 -GGATCCAGGCATTTT GATGC-3 0 , were used as Binding Site Primer to amplify the 113-nt fragment that rested 170 nt from the LMO1-binding site. The control primers, 5 0 -GATGGAACAGAACTTCCTGC-3 0 and 5 0 -CTGAAATGCCCTTAGGTGGT-3 0 , are for amplifying the sequence located in the 3 0 side of the binding site, about 13 kb in distance.
Knockdown experiments by small interfering RNA Several siRNA fragments were designed and the most effective one was selected by both RT-PCR analysis and reporter assay; for RUNX3 suppression: 5 0 -GAGUUUCACCCUGACCAU CAC-3 0 , for LMO1 suppression: 5 0 -CUGUGCUGCUUG CAG CAAG-3 0 , for GSDM suppression: 5 0 -GGGCUGCGUC CUGGCCUUU-3 0 . The control siRNA was designed as the RNAs with 2-base substitution, for RUNX3: 5 0 -GAGUUAC UCCCUGACCAUCAC-3 0 , for LMO1: 5 0 -CUGUUCUUCU UGCAGCAAG-3 0 , for GSDM: 5 0 -GGGCUUCUUCCUGG CCUUU-3 0 . Using Lipofectamine 2000 (Invitrogen), the siRNAs were introduced to HSC59, which was followed by TGF-b1 treatment (2 ng/ml).
Caspase assay
The HSC59 and MKN28 cells were prepared in a 96-well dish (5000 cells/well). The cells were transfected with the expression vector for sense or antisense GSDM, respectively. The caspase 3/7 assay was performed using the Caspase-Glo 3/7 Assay (Promega) at 24 h after transfection. A caspase inhibitor zVAD was used for obtaining positive control data. The experiment was repeated in triplicate. For the assay with gene suppression, the HSC59 cells were transfected with the siRNAs for GSDM, LMO1 and RUNX3 suppression (6 pmol/well), respectively. The caspase 3/7 assay was performed at 24 h after adding TGF-b1 (Sigma) into the medium (2 ng/ml).
Microscopic observation of LMO1/Runx3 localization in HSC59 nucleus
Both constructs, human LMO1 cDNA in pECFP-N1 plasmid (Clontech, Mountain View, CA, USA) and mouse Runx3 cDNA in pEYFP-C1 (Clontech), were introduced to HSC59 and observed using Zeiss LSM510 META Confocal Imaging System.
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